First AD

Second AD

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

My Treatment Approach: Metastatic Melanoma

Insights

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab

The Current State of Metastatic Melanoma

First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios

Closing Remarks on the Treatment of Patients With Metastatic Melanoma